|
|
 Previous Article | Table of Contents | Next Article 
Plasma cell karyotype in multiple myeloma
J Gould, R Alexanian, A Goodacre, S Pathak, B Hecht and B Barlogie
University of Texas, M.D. Anderson Hospital & Tumor Institute, Houston
77030.
Karyotypic abnormalities were studied in multiple myeloma and were
correlated with clinical features. Among 115 evaluable patients, 46% had an
abnormal karyotype. Trisomy 3, 5, 9, and 15 and monosomy 13 and 16 were the
most common clonal abnormalities. Translocations described previously in
other B cell malignancies occurred in nine patients, including four with
t(8;14)(q24;q32) translocations. The association of all t(8;14)
abnormalities with IgA protein type suggested a pathogenetic relationship
between a specific karyotypic abnormality and myeloma protein type.
Hypodiploidy occurred mainly in patients with only Bence Jones protein, was
associated with resistance to therapy, and justified the early
consideration of investigational therapies.
Volume 71,
Issue 2,
pp. 453-456,
02/01/1988
Copyright © 1988 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. G. Richardson, T. Hideshima, and K. C. Anderson
Plasma cell dyscrasias
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
298 - 327.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. Chng, S. A. Van Wier, G. J. Ahmann, J. M. Winkler, S. M. Jalal, P. L. Bergsagel, M. Chesi, M. C. Trendle, M. M. Oken, E. Blood, et al.
A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS
Blood,
September 15, 2005;
106(6):
2156 - 2161.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. N. Pearse, S. L. Swendeman, Y. Li, D. Rafii, and B. L. Hempstead
A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival
Blood,
June 1, 2005;
105(11):
4429 - 4436.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fonseca, B. Barlogie, R. Bataille, C. Bastard, P. L. Bergsagel, M. Chesi, F. E. Davies, J. Drach, P. R. Greipp, I. R. Kirsch, et al.
Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report
Cancer Res.,
February 15, 2004;
64(4):
1546 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Moreau, T. Facon, X. Leleu, N. Morineau, P. Huyghe, J.-L. Harousseau, R. Bataille, and H. Avet-Loiseau
Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy
Blood,
August 13, 2002;
100(5):
1579 - 1583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Avet-Loiseau, F. Gerson, F. Magrangeas, S. Minvielle, J.-L. Harousseau, and R. Bataille
Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors
Blood,
November 15, 2001;
98(10):
3082 - 3086.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. V. Smadja, C. Bastard, C. Brigaudeau, D. Leroux, and C. Fruchart
Hypodiploidy is a major prognostic factor in multiple myeloma
Blood,
October 1, 2001;
98(7):
2229 - 2238.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Shaughnessy Jr, E. Tian, J. Sawyer, K. Bumm, R. Landes, A. Badros, C. Morris, G. Tricot, J. Epstein, and B. Barlogie
High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH
Blood,
August 15, 2000;
96(4):
1505 - 1511.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Avet-Loiseau, J.-Y. Li, N. Morineau, T. Facon, C. Brigaudeau, J.-L. Harousseau, B. Grosbois, and R. Bataille
Monosomy 13 Is Associated With the Transition of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma
Blood,
October 15, 1999;
94(8):
2583 - 2589.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Avet-Loiseau, T. Facon, A. Daviet, C. Godon, M.-J. Rapp, J.-L. Harousseau, B. Grosbois, and R. Bataille
14q32 Translocations and Monosomy 13 Observed in Monoclonal Gammopathy of Undetermined Significance Delineate a Multistep Process for the Oncogenesis of Multiple Myeloma
Cancer Res.,
September 1, 1999;
59(18):
4546 - 4550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Drach, J. Ackermann, E. Fritz, E. Kromer, R. Schuster, H. Gisslinger, M. DeSantis, N. Zojer, M. Fiegl, S. Roka, et al.
Presence of a p53 Gene Deletion in Patients With Multiple Myeloma Predicts for Short Survival After Conventional-Dose Chemotherapy
Blood,
August 1, 1998;
92(3):
802 - 809.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hallek, P. Leif Bergsagel, and K. C. Anderson
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
Blood,
January 1, 1998;
91(1):
3 - 21.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Nishida, A. Tamura, N. Nakazawa, Y. Ueda, T. Abe, F. Matsuda, K. Kashima, and M. Taniwaki
The Ig Heavy Chain Gene Is Frequently Involved in Chromosomal Translocations in Multiple Myeloma and Plasma Cell Leukemia as Detected by In Situ Hybridization
Blood,
July 15, 1997;
90(2):
526 - 534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.H.L. Ng, Y.F. Chung, K.W. Lo, N.W.R. Wickham, J.C.K. Lee, and D.P. Huang
Frequent Hypermethylation of p16 and p15 Genes in Multiple Myeloma
Blood,
April 1, 1997;
89(7):
2500 - 2506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
